Characterization of stem cell landscape and assessing the stemness degree to aid clinical therapeutics in hematologic malignancies.
Bone marrow microenvironment
Drug sensitivity
Leukemia stem cell
Machine learning
hematologic malignancy
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
10 10 2024
10 10 2024
Historique:
received:
02
05
2024
accepted:
30
09
2024
medline:
11
10
2024
pubmed:
11
10
2024
entrez:
10
10
2024
Statut:
epublish
Résumé
Hematological malignancies are a group of cancers that affect the blood, bone marrow, and lymphatic system. Cancer stem cells (CSCs) are believed to be responsible for the initiation, progression, and relapse of hematological malignancies. However, identifying and targeting CSCs presents many challenges. We aimed to develop a stemness index (HSCsi) to identify and guide the therapy targeting CSCs in hematological malignancies. We developed a novel one-class logistic regression (OCLR) algorithm to identify transcriptomic feature sets related to stemness in hematologic malignancies. We used the HSCsi to measure the stemness degree of leukemia stem cells (LSCs) and correlate it with clinical outcomes.We analyze the correlation of HSCsi with genes and pathways involved in drug resistance and immune microenvironment of acute myeloid leukemia (AML). HSCsi revealed stemness-related biological mechanisms in hematologic malignancies and effectively identify LSCs. The index also predicted survival and relapse rates of various hematologic malignancies. We also identified potential drugs and interventions targeting cancer stem cells (CSCs) of hematologic malignancies by the index. Moreover, we found a correlation between stemness and bone marrow immune microenvironment in AML. Our study provides a novel method and tool to assess the stemness degree of hematologic malignancies and its implications for clinical outcomes and therapeutic strategies. Our HSC stemness index can facilitate the precise stratification of hematologic malignancies, suggest possible targeted and immunotherapy options, and guide the selection of patients.
Identifiants
pubmed: 39390242
doi: 10.1038/s41598-024-74806-6
pii: 10.1038/s41598-024-74806-6
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
23743Informations de copyright
© 2024. The Author(s).
Références
Malta, T. M. et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell. 173(338–54), e15 (2018).
Wang, Z. et al. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients. Brief. Bioinform. https://doi.org/10.1093/bib/bbab032 (2021).
doi: 10.1093/bib/bbab032
pubmed: 34459479
pmcid: 8769916
Chen, D. et al. Integrated machine learning and bioinformatic analyses constructed a novel stemness-related classifier to predict prognosis and immunotherapy responses for hepatocellular carcinoma patients. Int. J. Biol. Sci. 18, 360–373 (2022).
pubmed: 34975338
pmcid: 8692161
doi: 10.7150/ijbs.66913
Khoury, J. D. et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 36, 1703–1719 (2022).
pubmed: 35732831
pmcid: 9252913
doi: 10.1038/s41375-022-01613-1
Alaggio, R. et al. The 5th edition of the world health organization classification of haematolymphoid tumours: Lymphoid neoplasms. Leukemia. 36, 1720–1748 (2022).
pubmed: 35732829
pmcid: 9214472
doi: 10.1038/s41375-022-01620-2
O’Brien, C. A., Kreso, A. & Jamieson, C. H. Cancer stem cells and self-renewal. Clin Cancer Res. 16, 3113–3120 (2010).
pubmed: 20530701
doi: 10.1158/1078-0432.CCR-09-2824
Dick, J. E. Stem cell concepts renew cancer research. Blood. 112, 4793–4807 (2008).
pubmed: 19064739
doi: 10.1182/blood-2008-08-077941
Eppert, K. et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 17, 1086–1093 (2011).
pubmed: 21873988
doi: 10.1038/nm.2415
Zhang, Y. et al. Identification of biomarkers for acute leukemia via machine learning-based stemness index. Gene. 804, 145903 (2021).
pubmed: 34411647
doi: 10.1016/j.gene.2021.145903
Batlle, E. & Clevers, H. Cancer stem cells revisited. Nat. Med.Bold">23, 1124–1134 (2017).
pubmed: 28985214
doi: 10.1038/nm.4409
Sarry, J. E. et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. J. Clin. Invest. 121, 384–395 (2011).
pubmed: 21157036
doi: 10.1172/JCI41495
Zhou, H. M., Zhang, J. G., Zhang, X. & Li, Q. Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents. Signal. Transduct. Target Ther. 6, 62 (2021).
pubmed: 33589595
pmcid: 7884707
doi: 10.1038/s41392-020-00430-1
Sokolov, A., Paull, E. O. & Stuart, J. M. One-class detection of cell states in tumor subtypes. Pac. Symp. Biocomput. 21, 405–416 (2016).
pubmed: 26776204
pmcid: 4856035
Amaral, M. L., Erikson, G. A. & Shokhirev, M. N. BART: Bioinformatics array research tool. BMC Bioinform. 19, 296 (2018).
doi: 10.1186/s12859-018-2308-x
Huang, M. L., Hung, Y. H., Lee, W. M., Li, R. K. & Jiang, B. R. SVM-RFE based feature selection and Taguchi parameters optimization for multiclass SVM classifier. ScientificWorldJournal. 2014, 795624 (2014).
pubmed: 25295306
pmcid: 4175386
doi: 10.1155/2014/795624
Subramanian, A. et al. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell. 171, 1437–52.e17 (2017).
pubmed: 29195078
pmcid: 5990023
doi: 10.1016/j.cell.2017.10.049
Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
pubmed: 25605792
pmcid: 4402510
doi: 10.1093/nar/gkv007
Maeser, D., Gruener, R. F. & Huang, R. S. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief. Bioinform. https://doi.org/10.1093/bib/bbab260 (2021).
doi: 10.1093/bib/bbab260
pubmed: 34260682
pmcid: 8574972
Fu, J. et al. Large-scale public data reuse to model immunotherapy response and resistance. Genome Med. 12, 21 (2020).
pubmed: 32102694
pmcid: 7045518
doi: 10.1186/s13073-020-0721-z
Reich, M. et al. GenePattern 2.0. Nat. Genet. 38, 500–501 (2006).
pubmed: 16642009
doi: 10.1038/ng0506-500
Bindea, G. et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 39, 782–795 (2013).
pubmed: 24138885
doi: 10.1016/j.immuni.2013.10.003
Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013).
pubmed: 24113773
doi: 10.1038/ncomms3612
Toren, A. et al. CD133-positive hematopoietic stem cell “stemness” genes contain many genes mutated or abnormally expressed in leukemia. Stem Cells. 23, 1142–1153 (2005).
pubmed: 16140871
doi: 10.1634/stemcells.2004-0317
Venezia, T. A. et al. Molecular signatures of proliferation and quiescence in hematopoietic stem cells. PLoS Biol. 2, e301 (2004).
pubmed: 15459755
pmcid: 520599
doi: 10.1371/journal.pbio.0020301
Jung, N., Dai, B., Gentles, A. J., Majeti, R. & Feinberg, A. P. An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis. Nat. Commun. 6, 8489 (2015).
pubmed: 26444494
doi: 10.1038/ncomms9489
Gentles, A. J., Plevritis, S. K., Majeti, R. & Alizadeh, A. A. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA. 304, 2706–2715 (2010).
pubmed: 21177505
pmcid: 4089862
doi: 10.1001/jama.2010.1862
Mathur, D. et al. Analysis of the mouse embryonic stem cell regulatory networks obtained by ChIP-chip and ChIP-PET. Genome Biol. 9, R126 (2008).
pubmed: 18700969
pmcid: 2575516
doi: 10.1186/gb-2008-9-8-r126
Assou, S. et al. A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas. Stem Cells. 25, 961–973 (2007).
pubmed: 17204602
doi: 10.1634/stemcells.2006-0352
Hu, K. Quick, coordinated and authentic reprogramming of ribosome biogenesis during iPSC reprogramming. Cells. 9, 2484 (2020).
pubmed: 33203179
pmcid: 7697288
doi: 10.3390/cells9112484
Ming, X. Y. et al. Integrin α7 is a functional cancer stem cell surface marker in oesophageal squamous cell carcinoma. Nat. Commun. 7, 13568 (2016).
pubmed: 27924820
pmcid: 5150658
doi: 10.1038/ncomms13568
Pandey, S. et al. Sphingosine kinases protect murine embryonic stem cells from sphingosine-induced cell cycle arrest. Stem Cells. 38, 613–623 (2020).
pubmed: 31916656
doi: 10.1002/stem.3145
Trowbridge, J. J., Snow, J. W., Kim, J. & Orkin, S. H. DNA methyltransferase 1 is essential for and uniquely regulates hematopoietic stem and progenitor cells. Cell Stem Cell. 5, 442–449 (2009).
pubmed: 19796624
pmcid: 2767228
doi: 10.1016/j.stem.2009.08.016
Huang, F. F. et al. Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K/Akt pathway in adult acute leukemia. Cancer Lett. 336, 96–105 (2013).
pubmed: 23603434
doi: 10.1016/j.canlet.2013.04.006
Tamburini, J. et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood. 111, 379–382 (2008).
pubmed: 17878402
doi: 10.1182/blood-2007-03-080796
Pan, R. et al. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. Blood. 126, 363–372 (2015).
pubmed: 26045609
pmcid: 4504949
doi: 10.1182/blood-2014-10-604975
Perry, J. M. et al. Overcoming Wnt-beta-catenin dependent anticancer therapy resistance in leukaemia stem cells. Nat. Cell Biol. 22, 689–700 (2020).
pubmed: 32313104
pmcid: 8010717
doi: 10.1038/s41556-020-0507-y
Hayun, M. et al. Synergistic effect of AS101 and Bryostatin-1 on myeloid leukemia cell differentiation in vitro and in an animal model. Leukemia. 21, 1504–1513 (2007).
pubmed: 17508000
doi: 10.1038/sj.leu.2404746
Bodaar, K. et al. JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. Leukemia. 36, 1499–1507 (2022).
pubmed: 35411095
pmcid: 9177679
doi: 10.1038/s41375-022-01558-5
Jing, C. B. et al. Synthetic lethal targeting of TET2-mutant hematopoietic stem and progenitor cells (HSPCs) with TOP1-targeted drugs and PARP1 inhibitors. Leukemia. 34, 2992–3006 (2020).
pubmed: 32572188
doi: 10.1038/s41375-020-0927-5
Laverdière, I. et al. Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia. Blood Cancer J. 8, 52 (2018).
pubmed: 29921955
pmcid: 6889502
doi: 10.1038/s41408-018-0087-2
Nakaya, A. et al. The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-κB activity. Leuk. Res. 35, 243–249 (2011).
pubmed: 20542334
doi: 10.1016/j.leukres.2010.05.011
Shanmugam, M. K. et al. Celastrol attenuates the invasion and migration and augments the anticancer effects of bortezomib in a xenograft mouse model of multiple myeloma. Front. Pharmacol. 9, 365 (2018).
pubmed: 29773987
pmcid: 5943600
doi: 10.3389/fphar.2018.00365
Daver, N. et al. Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: A nonrandomized, open-label phase II study. Cancer Discov. 9, 370–383 (2019).
pubmed: 30409776
doi: 10.1158/2159-8290.CD-18-0774
Zhang, C. et al. Depiction of tumor stemlike features and underlying relationships with hazard immune infiltrations based on large prostate cancer cohorts. Brief. Bioinform. 22(3), bbaa211 (2021).
pubmed: 32856039
doi: 10.1093/bib/bbaa211
Chen, D. et al. Integrated machine learning and bioinformatic analyses constructed a novel stemness-related classifier to predict prognosis and immunotherapy responses for hepatocellular carcinoma patients. Int. J. Biol. Sci. 18(1), 360–373 (2022).
pubmed: 34975338
pmcid: 8692161
doi: 10.7150/ijbs.66913
Wang, Z. et al. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients. Brief. Bioinform. 22(5), bbab032 (2021).
pubmed: 33839757
pmcid: 8425448
doi: 10.1093/bib/bbab032
Zhang, Q. et al. Identification of cancer cell stemness-associated long noncoding RNAs for predicting prognosis of patients with hepatocellular carcinoma. DNA Cell Biol. 40(8), 1087–1100 (2021).
pubmed: 34096799
doi: 10.1089/dna.2021.0282
Ng, S. W. et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 540, 433–437 (2016).
pubmed: 27926740
doi: 10.1038/nature20598
Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730–737 (1997).
pubmed: 9212098
doi: 10.1038/nm0797-730
Taussig, D. C. et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood. 112, 568–575 (2008).
pubmed: 18523148
doi: 10.1182/blood-2007-10-118331
Park, E. K. et al. Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53. Cell Death Dis. 6, e1964 (2015).
pubmed: 26539911
pmcid: 4670923
doi: 10.1038/cddis.2015.313
Al-Mawali, A., Gillis, D. & Lewis, I. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones. J. Hematol. Oncol. 9, 61 (2016).
pubmed: 27465508
pmcid: 4964068
doi: 10.1186/s13045-016-0292-z
Zhang, B. et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell.Bold">21, 577–592 (2012).
pubmed: 22516264
pmcid: 3332001
doi: 10.1016/j.ccr.2012.02.018
Lee, M. O. & Cho, Y. S. The role of selenium-mediated redox signaling by selenophosphate synthetase 1 (SEPHS1) in hESCs. Biochem. Biophys. Res. Commun. 520, 406–412 (2019).
pubmed: 31607477
doi: 10.1016/j.bbrc.2019.09.123
Thoms, J. A. et al. ERG promotes T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell enhancer. Blood. 117, 7079–7089 (2011).
pubmed: 21536859
doi: 10.1182/blood-2010-12-317990
Calvanese, V. et al. MLLT3 governs human haematopoietic stem-cell self-renewal and engraftment. Nature. 576, 281–286 (2019).
pubmed: 31776511
pmcid: 7278275
doi: 10.1038/s41586-019-1790-2
Caiado, F., Pietras, E. M. & Manz, M. G. Inflammation as a regulator of hematopoietic stem cell function in disease, aging, and clonal selection. J. Exp. Med. https://doi.org/10.1084/jem.20201541 (2021).
doi: 10.1084/jem.20201541
pubmed: 34129016
pmcid: 8210622
Yamashita, M. & Passegué, E. TNF-α coordinates hematopoietic stem cell survival and myeloid regeneration. Cell Stem Cell. 25, 357–72.e7 (2019).
pubmed: 31230859
pmcid: 6733032
doi: 10.1016/j.stem.2019.05.019
Yang, L. et al. IFN-gamma negatively modulates self-renewal of repopulating human hemopoietic stem cells. J. Immunol. 174, 752–757 (2005).
pubmed: 15634895
doi: 10.4049/jimmunol.174.2.752
Lee, J. Y. et al. mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion. Cell Stem Cell. 7, 593–605 (2010).
pubmed: 21040901
pmcid: 2995996
doi: 10.1016/j.stem.2010.09.015
Magee, J. A. et al. Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression. Cell Stem Cell. 11, 415–428 (2012).
pubmed: 22958933
pmcid: 3447536
doi: 10.1016/j.stem.2012.05.026
Ames, K. et al. PI3-kinase deletion promotes myelodysplasia by dysregulating autophagy in hematopoietic stem cells. Sci. Adv. 9, eade8222 (2023).
pubmed: 36812307
pmcid: 9946350
doi: 10.1126/sciadv.ade8222
Perry, J. M. et al. Overcoming Wnt-β-catenin dependent anticancer therapy resistance in leukaemia stem cells. Nat. Cell Biol. 22, 689–700 (2020).
pubmed: 32313104
pmcid: 8010717
doi: 10.1038/s41556-020-0507-y
Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F. & Okkenhaug, K. PI3K inhibitors are finally coming of age. Nat. Rev. Drug Discov. 20, 741–769 (2021).
pubmed: 34127844
pmcid: 9297732
doi: 10.1038/s41573-021-00209-1
Hanker, A. B., Kaklamani, V. & Arteaga, C. L. Challenges for of the clinical development PI3K inhibitors: strategies to improve their impact in solid tumors. Cancer Discov. 9, 482–491 (2019).
pubmed: 30867161
pmcid: 6445714
doi: 10.1158/2159-8290.CD-18-1175
Rozengurt, E., Soares, H. P. & Sinnet-Smith, J. Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. Mol. Cancer Ther. 13, 2477–2488 (2014).
pubmed: 25323681
pmcid: 4222988
doi: 10.1158/1535-7163.MCT-14-0330
Bojarczuk, K. et al. Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. Blood. 133, 70–80 (2019).
pubmed: 30322870
pmcid: 6318426
doi: 10.1182/blood-2018-08-872465
Ye, Y. et al. The genomic landscape and pharmacogenomic interactions of clock genes in cancer chronotherapy. Cell Syst. 6, 314–28.e2 (2018).
pubmed: 29525205
pmcid: 6056007
doi: 10.1016/j.cels.2018.01.013
Zeidan, A. M. et al. Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study. Blood. 134, 829 (2019).
doi: 10.1182/blood-2019-122896
Ravandi, F. et al. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 6, e480–e488 (2019).
pubmed: 31400961
pmcid: 6778960
doi: 10.1016/S2352-3026(19)30114-0
Esposito, M. T. et al. Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors. Nature medicine. 21, 1481–1490 (2015).
pubmed: 26594843
doi: 10.1038/nm.3993
Bayik, D. & Lathia, J. D. Cancer stem cell-immune cell crosstalk in tumour progression. Nat. Rev. Cancer. 21, 526–536 (2021).
pubmed: 34103704
pmcid: 8740903
doi: 10.1038/s41568-021-00366-w
Miranda, A. et al. Cancer stemness, intratumoral heterogeneity, and immune response across cancers. Proc. Natl. Acad. Sci. USA. 116, 9020–9029 (2019).
pubmed: 30996127
pmcid: 6500180
doi: 10.1073/pnas.1818210116
Mussai, F. et al. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood. 122, 749–758 (2013).
pubmed: 23733335
pmcid: 3731930
doi: 10.1182/blood-2013-01-480129
Deng, M. et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 562, 605–609 (2018).
pubmed: 30333625
pmcid: 6296374
doi: 10.1038/s41586-018-0615-z